ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8 | -94.1% | 694 | -89.1% | 0.00% | -100.0% |
| Q2 2023 | $136 | -43.8% | 6,340 | +5.7% | 0.00% | -50.0% |
| Q1 2023 | $242 | -13.3% | 5,998 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $279 | -99.9% | 5,998 | +38.2% | 0.00% | 0.0% |
| Q3 2022 | $225,000 | -20.8% | 4,341 | +8.8% | 0.00% | 0.0% |
| Q1 2022 | $284,000 | -4.7% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $298,000 | +31.3% | 3,989 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $227,000 | +29.0% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $176,000 | -10.7% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $197,000 | +17.3% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $168,000 | -8.2% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $183,000 | -8.5% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $200,000 | -2.4% | 3,989 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $205,000 | -16.7% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $246,000 | +2.5% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $240,000 | -28.8% | 3,989 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $337,000 | -11.5% | 3,989 | 0.0% | 0.00% | -20.0% |
| Q1 2019 | $381,000 | +34.6% | 3,989 | 0.0% | 0.01% | +25.0% |
| Q4 2018 | $283,000 | -17.0% | 3,989 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $341,000 | -29.8% | 3,989 | -4.8% | 0.00% | -33.3% |
| Q2 2018 | $486,000 | +43.4% | 4,189 | 0.0% | 0.01% | +50.0% |
| Q1 2018 | $339,000 | +114.6% | 4,189 | +55.1% | 0.00% | +100.0% |
| Q4 2017 | $158,000 | +25.4% | 2,700 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $126,000 | +29.9% | 2,700 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $97,000 | +16.9% | 2,700 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $83,000 | -7.8% | 2,700 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $90,000 | +25.0% | 2,700 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $72,000 | +20.0% | 2,700 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $60,000 | -36.2% | 2,700 | -15.6% | 0.00% | 0.0% |
| Q1 2016 | $94,000 | -47.2% | 3,200 | -40.7% | 0.00% | -50.0% |
| Q4 2015 | $178,000 | -8.7% | 5,400 | 0.0% | 0.00% | -33.3% |
| Q3 2015 | $195,000 | – | 5,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |